JP2010168283A - ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤 - Google Patents

ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤 Download PDF

Info

Publication number
JP2010168283A
JP2010168283A JP2007114293A JP2007114293A JP2010168283A JP 2010168283 A JP2010168283 A JP 2010168283A JP 2007114293 A JP2007114293 A JP 2007114293A JP 2007114293 A JP2007114293 A JP 2007114293A JP 2010168283 A JP2010168283 A JP 2010168283A
Authority
JP
Japan
Prior art keywords
liver
natriuretic peptide
liver fibrosis
anp
hepatic stellate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007114293A
Other languages
English (en)
Japanese (ja)
Inventor
Isao Sakaida
功 坂井田
Takaji Terai
崇二 寺井
Naoki Yamamoto
直樹 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Asubio Pharma Co Ltd
Yamaguchi University NUC
Original Assignee
Daiichi Sankyo Co Ltd
Asubio Pharma Co Ltd
Yamaguchi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Asubio Pharma Co Ltd, Yamaguchi University NUC filed Critical Daiichi Sankyo Co Ltd
Priority to JP2007114293A priority Critical patent/JP2010168283A/ja
Priority to PCT/JP2008/058322 priority patent/WO2008133349A1/fr
Publication of JP2010168283A publication Critical patent/JP2010168283A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007114293A 2007-04-24 2007-04-24 ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤 Withdrawn JP2010168283A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007114293A JP2010168283A (ja) 2007-04-24 2007-04-24 ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤
PCT/JP2008/058322 WO2008133349A1 (fr) 2007-04-24 2008-04-24 Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007114293A JP2010168283A (ja) 2007-04-24 2007-04-24 ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤

Publications (1)

Publication Number Publication Date
JP2010168283A true JP2010168283A (ja) 2010-08-05

Family

ID=39925788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007114293A Withdrawn JP2010168283A (ja) 2007-04-24 2007-04-24 ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤

Country Status (2)

Country Link
JP (1) JP2010168283A (fr)
WO (1) WO2008133349A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099258A1 (fr) 2011-01-21 2012-07-26 株式会社 イギス Agent thérapeutique pour l'alopécie
JPWO2013027680A1 (ja) * 2011-08-19 2015-03-19 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
US9358269B2 (en) 2009-07-23 2016-06-07 Igisu Co., Ltd Method for treating dermatitis and improving skin texture using natriuretic peptides
CN107261119A (zh) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358269B2 (en) 2009-07-23 2016-06-07 Igisu Co., Ltd Method for treating dermatitis and improving skin texture using natriuretic peptides
US9968654B2 (en) 2009-07-23 2018-05-15 Igisu Co., Ltd. Method of treatment dermatitis with c-type natriuretic peptide derivatives
US10946072B2 (en) 2009-07-23 2021-03-16 Igisu Co., Ltd. Method for treating dermatitis and improving skin texture using B-type natriuretic peptides
WO2012099258A1 (fr) 2011-01-21 2012-07-26 株式会社 イギス Agent thérapeutique pour l'alopécie
KR20140041437A (ko) 2011-01-21 2014-04-04 쿄고 엔도 탈모증 치료제
US9480728B2 (en) 2011-01-21 2016-11-01 Igisu Co., Ltd. Agent for the treatment of alopecia
US9808511B2 (en) 2011-01-21 2017-11-07 Igisu Co., Ltd. Method for treating alopecia with B-type natriuretic peptide
US11571464B2 (en) 2011-01-21 2023-02-07 Igisu Co., Ltd. C-type natriuretic peptide agent for the treatment of alopecia
CN107261119A (zh) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
JPWO2013027680A1 (ja) * 2011-08-19 2015-03-19 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬

Also Published As

Publication number Publication date
WO2008133349A1 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
Umar et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension
Dostal et al. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?
KR102559262B1 (ko) 심근증, 진구성 심근경색 및 만성심부전의 치료약
WO2006115274A1 (fr) Inducteur de differenciation des progeniteurs myeloerythroides
US7659249B2 (en) Membrane-permeable NFAT inhibitory peptide
JP2010168283A (ja) ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤
Biolo et al. Pentoxifylline acutely reduces protein catabolism in chronically uremic patients
WO2006134692A1 (fr) Agent angiogénétique contenant de l’adrénoméduline comme principe actif
Zhu et al. Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-β1/Smad signaling
EP3878470A1 (fr) Procédé d'élimination de cellules sénescentes et procédé de préparation de cellules sénescentes
Konturek et al. Expression of transforming growth factor-beta1 and epidermal growth factor in caerulein-induced pancreatitis in rat
JP5207316B2 (ja) 腹膜線維化抑制用医薬組成物
US8361966B2 (en) Use of interleukin-11 as therapeutic agent for heart disease
US7423019B2 (en) Agent for inducing conversion of intestinal cells into insulin-producing cells and antidiabetic drug
JP6110587B2 (ja) 腹膜癒着防止用医薬組成物
US20100210713A1 (en) Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
Yang et al. The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights
EP2344181A1 (fr) Utilisation de ctgf comme cardioprotecteur
Krämer et al. Role of endothelin in hypertension
YONEZAWA Discrepancy between the potency of various trypsin inhibitors to inhibit trypsin activity and the potency to release biologically active cholecystokinin-pancreozymin
KR101780597B1 (ko) TIF1γ의 발현 또는 활성 증강제를 유효성분으로 포함하는 간 섬유화 또는 간경화 예방 또는 치료용 조성물
WO2020010958A1 (fr) Application d'une protéine ou d'un gène metrnl dans une maladie caractérisée par l'obstruction d'un vaisseau sanguin
Editors Hypertension Editors’ Picks: Novel Drugs
CN110339344B (zh) 核受体Rev-erbα在制备抗血小板药物中的应用
Wegner et al. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20100803